Insmed (INSM) Consolidated Net Income (2010 - 2026)
Insmed (INSM) posted Consolidated Net Income of -$13.3 million for Q2 2026, up 91.89% on a QoQ basis from -$163.6 million in Q1 2026, and up 95.87% year-over-year from -$6.8 million in Q2 2025.
Analysis
Insmed (INSM) Consolidated Net Income (2010 - 2026) Analysis & Trends
Insmed has reported Consolidated Net Income for 17 years, with the latest figure at -$13.3 million in Q2 2026.
- On a quarterly basis, Consolidated Net Income rose 95.87% year-over-year to -$13.3 million in Q2 2026; TTM through Jun 2026 was -$875.4 million, a 15.37% increase from a year earlier, with the FY2025 full-year figure at -$1.3 billion, down 39.73% from the prior year.
- Consolidated Net Income was -$13.3 million for Q2 2026 at Insmed, up from -$163.6 million in the prior quarter.
- The five-year high for Consolidated Net Income was -$13.3 million in Q2 2026, with the low at -$370.0 million in Q3 2025.
- Average Consolidated Net Income over 5 years is -$199.9 million, with a median of -$174.8 million recorded in 2023.
- The sharpest annual moves came in 2023 and 2026: Consolidated Net Income plunged 155.96% in 2023, then soared 95.87% in 2026.
- Over 5 years, Consolidated Net Income stood at -$160.1 million in 2022, then retreated by 16.22% to -$186.1 million in 2023, then decreased by 26.6% to -$235.5 million in 2024, then plunged by 39.45% to -$328.5 million in 2025, then soared by 95.96% to -$13.3 million in 2026.
- The last three Consolidated Net Income figures came in at -$13.3 million (Q2 2026), -$163.6 million (Q1 2026), and -$328.5 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Consol Net Inc. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 2.38 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | -10.50 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | 1.10 Bn |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.30 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | 601.00 Mn |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | -782.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 97.50 Mn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | -13.27 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | -1.04 Bn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -13.27 Mn |
| Mar 31, 2026 | -163.60 Mn |
| Dec 31, 2025 | -328.46 Mn |
| Sep 30, 2025 | -370.02 Mn |
| Jun 30, 2025 | -321.69 Mn |
| Mar 31, 2025 | -256.58 Mn |
| Dec 31, 2024 | -235.55 Mn |
| Sep 30, 2024 | -220.52 Mn |
| Jun 30, 2024 | -300.61 Mn |
| Mar 31, 2024 | -157.10 Mn |
| Dec 31, 2023 | -186.06 Mn |
| Sep 30, 2023 | -158.93 Mn |
| Jun 30, 2023 | -244.81 Mn |
| Mar 31, 2023 | -159.78 Mn |
| Dec 31, 2022 | -160.10 Mn |
| Sep 30, 2022 | -131.17 Mn |
| Jun 30, 2022 | -95.65 Mn |
| Mar 31, 2022 | -94.64 Mn |
| Dec 31, 2021 | -112.94 Mn |
| Sep 30, 2021 | -112.69 Mn |